BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6] [Cited by in Crossref: 217] [Cited by in F6Publishing: 87] [Article Influence: 43.4] [Reference Citation Analysis]
Number Citing Articles
1 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
2 Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684 [PMID: 30386460 DOI: 10.4254/wjh.v10.i10.670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
3 Chen J, Chiu Y, Lee P, Tung H, Chiu H, Chien S, Cheng P. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.04.020] [Reference Citation Analysis]
4 Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
5 Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-237. [PMID: 29116550 DOI: 10.1007/s11904-017-0369-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
6 Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat 2019;26:951-60. [PMID: 30977945 DOI: 10.1111/jvh.13110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
7 Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. Gut Liver 2021;15:440-50. [PMID: 32839365 DOI: 10.5009/gnl19393] [Reference Citation Analysis]
8 Brown A, Welzel TM, Conway B, Negro F, Bräu N, Grebely J, Puoti M, Aghemo A, Kleine H, Pugatch D, Mensa FJ, Chen YJ, Lei Y, Lawitz E, Asselah T. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. Liver Int 2020;40:778-86. [PMID: 31568620 DOI: 10.1111/liv.14266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
10 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
11 Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J 2021;18:69. [PMID: 34193156 DOI: 10.1186/s12954-021-00519-y] [Reference Citation Analysis]
12 Luxenburger H, Neumann-Haefelin C, Thimme R, Boettler T. HCV-Specific T Cell Responses During and After Chronic HCV Infection. Viruses 2018;10:E645. [PMID: 30453612 DOI: 10.3390/v10110645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
13 Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. [DOI: 10.1007/s00535-021-01845-5] [Reference Citation Analysis]
14 Wong A, Tsien C, Mansour S, Cooper C. Remaining clinical issues in hepatitis C treatment. CanLivJ 2018;1:66-77. [DOI: 10.3138/canlivj.1.2.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
16 Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 2018;15:180. [PMID: 30466446 DOI: 10.1186/s12985-018-1094-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
17 Couri T, Aronsohn A. When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients. Clin Liver Dis (Hoboken) 2019;14:131-4. [PMID: 31709040 DOI: 10.1002/cld.849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C, Hierro L, Kelly D, Ling SC, Strokova T, Del Valle-Segarra A, Lovell S, Liu W, Ng TI, Porcalla A, Gonzalez YS, Burroughs M, Sokal E. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study. Hepatology. 2020;71:456-462. [PMID: 31254392 DOI: 10.1002/hep.30840] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
19 Ito T. Editorial: impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis-a prospective serial follow-up MRI study. Aliment Pharmacol Ther 2020;52:735-6. [PMID: 32886380 DOI: 10.1111/apt.15911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Minami T, Tateishi R, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Hanajiri K, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Ohki T, Arai M, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Koike Y, Akamatsu M, Mitsui H, Fujie H, Ogura K, Yoshida H, Wada T, Kurai K, Maekawa H, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Moriya K, Yotsuyanagi H, Koike K. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer 2021;10:309-19. [PMID: 34414119 DOI: 10.1159/000513705] [Reference Citation Analysis]
21 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
22 Yeon JE. Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. Clin Mol Hepatol 2018;24:278-93. [PMID: 29716179 DOI: 10.3350/cmh.2018.1002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
23 Totsuka M, Honda M, Kanda T, Ishii T, Matsumoto N, Yamana Y, Kaneko T, Mizutani T, Takahashi H, Kumagawa M, Sasaki R, Masuzaki R, Kanezawa S, Nirei K, Yamagami H, Matsuoka S, Ohnishi H, Okamoto H, Moriyama M. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. Intern Med 2021;60:2061-6. [PMID: 33518580 DOI: 10.2169/internalmedicine.6728-20] [Reference Citation Analysis]
24 Zuckerman A, Chastain CA, Naggie S. Retreatment Options Following HCV Direct Acting Antiviral Failure. Curr Treat Options Infect Dis 2017;9:389-402. [PMID: 29242710 DOI: 10.1007/s40506-017-0136-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
25 Kimura K. Long-awaited treatment for hepatitis C virus decompensated cirrhosis. J Gastroenterol 2019;54:299-300. [PMID: 30599052 DOI: 10.1007/s00535-018-01538-6] [Reference Citation Analysis]
26 Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther 2018;47:1023-31. [PMID: 29377245 DOI: 10.1111/apt.14527] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
27 Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Dig Dis Sci 2021;66:1315-26. [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Real LM, Macías J, Pérez AB, Merino D, Granados R, Morano L, Delgado M, Ríos MJ, Galera C, Deltoro MG, Merchante N, García F, Pineda JA. Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. Sci Rep 2018;8:14905. [PMID: 30297726 DOI: 10.1038/s41598-018-33367-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, Zeng YH, Huang SP, Hsu YC, Wu SS, Siao FY, Yen HH. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021;10:5236. [PMID: 34830518 DOI: 10.3390/jcm10225236] [Reference Citation Analysis]
30 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62:pii: e02217-17. [PMID: 29180522 DOI: 10.1128/aac.02217-17:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 2019;54:916-27. [PMID: 30903385 DOI: 10.1007/s00535-019-01575-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
32 Anwaar MU, Adnan F, Abro A, Khan RA, Rehman AU, Osama M, Rainville C, Kumar S, Sterner DE, Javed S, Jamal SB, Baig A, Shabbir MR, Ahsan W, Butt TR, Assir MZ. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2. Comput Biol Med 2022;141:105049. [PMID: 34823857 DOI: 10.1016/j.compbiomed.2021.105049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Wörns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis 2019;69:1657-64. [PMID: 30923816 DOI: 10.1093/cid/ciz022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
34 Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67:1010-1017. [PMID: 29566246 DOI: 10.1093/cid/ciy220] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 24.3] [Reference Citation Analysis]
35 Kracht PAM, Arends JE, Hoepelman AIM, Vervoort SCJM. The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study. PLoS One 2020;15:e0230756. [PMID: 32282805 DOI: 10.1371/journal.pone.0230756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Howe AYM, Ceccherini-Silberstein F, Dietz J, Popping S, Grebely J, Rodrigo C, Lennerstrand J, Douglas MW, Parczewsk M, Harrigan PR, Pawlotsky JM, Garcia F, Collaborators S. SHARED: An International Collaboration to Unravel Hepatitis C Resistance. Viruses 2021;13:1580. [PMID: 34452444 DOI: 10.3390/v13081580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, Zadeikis N, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019;14:e0208506. [PMID: 30601818 DOI: 10.1371/journal.pone.0208506] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
38 Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy 2019;72:160-8. [PMID: 31085063 DOI: 10.1016/j.drugpo.2019.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
39 Ueda Y, Kobayashi T, Ikegami T, Miuma S, Mizuno S, Akamatsu N, Takaki A, Ishigami M, Takatsuki M, Sugawara Y, Maehara Y, Uemoto S, Seno H. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. J Gastroenterol 2019;54:660-6. [PMID: 30806783 DOI: 10.1007/s00535-019-01561-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
40 Brown RS Jr, Collins MA, Strasser SI, Emmett A, Topp AS, Burroughs M, Ferreira R, Feld JJ. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther 2022. [PMID: 35174470 DOI: 10.1007/s40121-022-00599-8] [Reference Citation Analysis]
41 Tanaka Y, Tateishi R, Koike K. Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature. Clin J Gastroenterol 2019;12:588-91. [PMID: 31134448 DOI: 10.1007/s12328-019-00997-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections. Adv Ther 2019;36:2475-86. [PMID: 31240629 DOI: 10.1007/s12325-019-01012-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
43 AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018;67:1477-92. [PMID: 30215672 DOI: 10.1093/cid/ciy585] [Cited by in Crossref: 277] [Cited by in F6Publishing: 243] [Article Influence: 92.3] [Reference Citation Analysis]
44 Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holten J, Xie F, Druyts E. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. [PMID: 31922124 DOI: 10.1016/j.eclinm.2019.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
45 Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
46 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
47 Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int 2020;14:225-38. [PMID: 32128704 DOI: 10.1007/s12072-020-10019-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
48 Corcorran MA, Tsui JI, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Drug Alcohol Depend 2021;220:108525. [PMID: 33461152 DOI: 10.1016/j.drugalcdep.2021.108525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Pritchard H, Jandhyala D, Hosry J, Angelidakis G, Torres HA. Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct-acting antivirals-A prospective study. JGH Open 2020;4:541-4. [PMID: 32514467 DOI: 10.1002/jgh3.12294] [Reference Citation Analysis]
50 Levien TL, Baker DE. Formulary Drug Reviews: Glecaprevir/Pibrentasvir. Hosp Pharm 2018;53:75-84. [PMID: 29581598 DOI: 10.1177/0018578717746417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther 2018;40:1234-45. [PMID: 29983266 DOI: 10.1016/j.clinthera.2018.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
52 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
53 Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 2018;32:868-902. [PMID: 29945886 DOI: 10.1101/gad.314849.118] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
54 Beisel C, Herrmann M, Piecha F, Lampalzer S, Buescher G, Pischke S, Schulze zur Wiesch J. Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110077] [Reference Citation Analysis]
55 Kosloski MP, Wang H, Pugatch D, Mensa FJ, Gane E, Lawitz E, Marbury TC, Preston RA, Kort J, Liu W. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. Eur J Clin Pharmacol 2019;75:217-26. [PMID: 30341499 DOI: 10.1007/s00228-018-2576-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307. [PMID: 29672891 DOI: 10.1002/hep.30046] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
57 Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Shen C, Fan H, Ge Z, Cai W, Shao J, Dong C, Xue H, Fu Z, Li J, Zhang Y, Yue M. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med (Lausanne) 2020;7:592472. [PMID: 33425940 DOI: 10.3389/fmed.2020.592472] [Reference Citation Analysis]
59 Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther 2021;38:1690-700. [PMID: 33590445 DOI: 10.1007/s12325-021-01647-4] [Reference Citation Analysis]
60 Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, Verbon A, Boucher CAB, Nichols BE, van de Vijver DAMC. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One 2019;14:e0210179. [PMID: 30629662 DOI: 10.1371/journal.pone.0210179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
61 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
62 Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells. 2019;8. [PMID: 30987413 DOI: 10.3390/cells8040313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
63 Hara T, Ohara T, Taniguchi M, Sakai H, Oka K, Iwai N, Tsuji T, Okuda T, Nagata A, Komaki T, Sakagami J, Kagawa K. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. Intern Med 2021;60:2437-43. [PMID: 33612683 DOI: 10.2169/internalmedicine.6664-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched. World J Gastroenterol 2021; 27(21): 2771-2783 [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
65 Abd Alla MDA, Dawood RM, Rashed HAE, Farrag G, Ammar IAE, Mahmoud MMA, Salum GM, Altanbouly AMA, El Meguid MA, Awady MKE. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Arch Virol 2021;166:1071-81. [PMID: 33533976 DOI: 10.1007/s00705-021-04969-4] [Reference Citation Analysis]
66 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62. [PMID: 29180522 DOI: 10.1128/aac.02217-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
67 Liu X, Hu P. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. J Clin Transl Hepatol 2021;9:125-32. [PMID: 33604263 DOI: 10.14218/JCTH.2020.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Hung HY, Hung WL, Shih CL, Chen CY. Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis. Ann Med 2022;54:108-20. [PMID: 34969349 DOI: 10.1080/07853890.2021.2012589] [Reference Citation Analysis]
69 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
70 Ashhab AA, Rodin H, Campos M, Abu-Sulb A, Hall JA, Powell J, Debes JD. Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection. PLoS One 2020;15:e0237398. [PMID: 32845914 DOI: 10.1371/journal.pone.0237398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
72 Hamed M, El-Hasab M, Mansour FR. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors. Virusdisease 2021;:1-7. [PMID: 33948452 DOI: 10.1007/s13337-021-00691-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Örmeci N, Gülşen MT, Sezgin O, Aghayeva S, Demir M, Köksal I, Güner R, Erarslan E, Asiller ÖÖ, Balkan A, Yaraş S, Çalışkan Kartal A. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020;31:148-55. [PMID: 32141824 DOI: 10.5152/tjg.2020.19440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
75 Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319-1329. [PMID: 30704789 DOI: 10.1016/s0140-6736(18)32277-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 52] [Article Influence: 38.7] [Reference Citation Analysis]
76 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
77 . Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr 2018;41:169-70. [PMID: 30410216 DOI: 10.18773/austprescr.2018.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
78 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
79 Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver Int 2019;39:826-34. [PMID: 30499631 DOI: 10.1111/liv.14014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
80 Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol 2020;11:710. [PMID: 32508646 DOI: 10.3389/fphar.2020.00710] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
82 Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557 [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
83 Karpel HC, Ali NM, Lawson N, Tatapudi VS, Friedlander R, Philogene MC, Montgomery RA, Lonze BE. Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor. Case Rep Transplant 2020;2020:3591274. [PMID: 32231847 DOI: 10.1155/2020/3591274] [Reference Citation Analysis]
84 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
85 Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Nguyen T, Hung Le M, Pham TT, Mensa F, Asselah T. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver Int 2020;40:2385-93. [PMID: 32445613 DOI: 10.1111/liv.14535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
87 Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 2019;54:291-6. [DOI: 10.1007/s00535-018-1520-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
88 Zamor PJ, Brown A, Dylla DE, Dillon JF, Luetkemeyer AF, Feld JJ, Mutimer D, Ghalib R, Crown E, Lovell SS, Hu Y, Moreno C, Nelson DR, Colombo M, Papatheodoridis G, Rockstroh JK, Skoien R, Lawitz E, Jacobson IM. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. Am J Gastroenterol 2021;116:1896-904. [PMID: 34465693 DOI: 10.14309/ajg.0000000000001332] [Reference Citation Analysis]
89 Lee DH, Ryu SH, Myung HJ, Shin YJ, Lee SH, Park TY, Moon JS. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. Korean J Gastroenterol 2021;77:88-91. [PMID: 33633000 DOI: 10.4166/kjg.2020.145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study. J Korean Med Sci 2021;36:e142. [PMID: 34060258 DOI: 10.3346/jkms.2021.36.e142] [Reference Citation Analysis]
91 Chang KC, Tung SY, Wei KL, Shen CH, Hsieh YY, Chen WM, Chen YH, Chen CH, Yen CW, Xu HW, Tung WL, Hung CH, Lu SN, Chang TS. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci Rep 2021;11:13543. [PMID: 34188161 DOI: 10.1038/s41598-021-93095-x] [Reference Citation Analysis]
92 Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. J Gastroenterol 2019;54:641-9. [PMID: 30778716 DOI: 10.1007/s00535-019-01556-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
93 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
94 Xu HQ, Wang CG, Xiao P, Gao YH. Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis. J Clin Transl Hepatol 2020;8:267-76. [PMID: 33083249 DOI: 10.14218/JCTH.2020.00047] [Reference Citation Analysis]
95 Deutsch L, Houri I, Ben-Ari Z, Shlomai A, Veitsman E, Cohen-Ezra O, Issachar A, Mor O, Gozlan Y, Bruck R, Menachem Y, Zelber-Sagi S, Katchman H, Shibolet O. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC Infect Dis 2020;20:264. [PMID: 32245397 DOI: 10.1186/s12879-020-4921-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2019;68:721-8. [PMID: 29666174 DOI: 10.1136/gutjnl-2017-315906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
97 Kosloski MP, Zhao W, Marbury TC, Preston RA, Collins MG, Pugatch D, Mensa F, Kort J, Liu W. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects. Antimicrob Agents Chemother 2018;62:e01990-17. [PMID: 29263061 DOI: 10.1128/AAC.01990-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
98 Qin YJ, Sha RC, Feng YC, Huang YC. Comparison of double antigen sandwich and indirect enzyme-linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies. J Clin Lab Anal 2020;34:e23481. [PMID: 33245583 DOI: 10.1002/jcla.23481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. PLoS One 2020;15:e0229239. [PMID: 32155165 DOI: 10.1371/journal.pone.0229239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
100 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]